You are currently viewing a new version of our website. To view the old version click .
Livers
  • Correction
  • Open Access

27 February 2025

Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568

,
,
and
1
Department of Gastroenterology, Kameda Daiichi Hospital, 2-5-22 Nishimachi, Konan-ku, Niigata City 9500165, Niigata, Japan
2
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-754 Asahimachidori, Niigata City 9518520, Niigata, Japan
*
Author to whom correspondence should be addressed.

Error in Table 4

In the original publication [1], there was a mistake in Table 4 (entitled “Changes in clinical parameters before and after pemafibrate therapy”) as published. The BMI “After” value was incorrect. The corrected Table 4 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Table 4. Changes in clinical parameters before and after pemafibrate therapy.

Reference

  1. Watanabe, A.; Horigome, R.; Nakatsuka, Y.; Terai, S. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.